The Promise Of Low Dose Naltrexone Therapy

Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 for opiate and drug abuse treatment. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn’s disease and certain cancers, to reduce symptoms in multiple sclerosis and autism, and to improve numerous autoimmune and neurodegenerative conditions, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Grounded in clinical and scientific research, this book describes the history of naltrexone, its potential therapeutic uses, its effects on the immune system, its pharmacological properties, and how the drug is administered. It also lists fillers and compounding pharmacies, doctors who prescribe LDN, and patient resources, and includes interviews with LDN patients and researchers.

A comprehensive examination of Low Dose Naltrexone—a little-known drug with big potential "[LDN] raises hopes of reversing memory loss in old age."—the Guardian A drug that is simultaneously affordable, devoid of severe side effects, and applicable to a wide range of diseases is not often found in the modern pharmaceutical landscape. But as medical professionals and researchers alike continue to discover, Low Dose Naltrexone (LDN) boasts this remarkable combination. LDN, originally prescribed in higher doses as a treatment for opioid addiction, works by blocking opioid receptors, thereby stimulating the production of endorphins, mitigating the inflammatory process, and stabilizing the immune response. Prescribed off-label and administered in small daily doses, this generic drug has proven useful in treating many different ailments. Expanding on the information presented in The LDN Book, Volume 1, which showcased LDN’s efficacy in treating conditions such as lupus, thyroiditis, autism spectrum disorder, and chronic fatigue, Volume 2 highlights the latest clinical trials, case studies, and research with explanations from a dozen medical professionals on how they are using LDN to help patients suffering from: Chronic pain Parkinson’s disease Dermatologic conditions Traumatic brain injury Lyme disease and more The LDN Book, Volume 2 is both a resource for practitioners, pharmacists, and patients, and a renewed call for further research on the healing potential of this generic drug.

Low Dose Naltrexone (LDN) holds the potential to help millions of people suffering from various autoimmune diseases and cancers, and even autism, chronic fatigue, and depression, find relief. Administered off-label in small daily doses (0.5 to 4.5 mg), this generic drug is extremely affordable and presents few known side effects. So why has it languished in relative medical obscurity? The LDN Book explains the drug’s origins, its primary mechanism, and the latest research from practicing physicians and pharmacists as compiled by Linda Elsegood of The LDN Research Trust, the world’s largest LDN charity organization with over 19,000 members worldwide. Featuring ten chapters contributed by medical professionals on LDN’s efficacy and two patient-friendly appendices, The LDN Book is a comprehensive resource for doctors, pharmacists, and patients who want to learn more about how LDN is helping people now, and a clarion call for further research that could help millions more.

LDN (Low Dose Naltrexone) is a proven-safe (by the FDA in 50mg doses!) off-label prescription drug which has gained a great deal of attention over the past few months due to its remarkable disease modifying effects of controlling and reversing symptoms of Parkinson's Disease. Lexie is one person who has experienced a reversal of most of her Parkinsons Disease symptoms over the past 5 years. She was officially diagnosed with Parkinsons disease in 2008 (although her non-motor symptoms began 20 years earlier). In this question and answer format with Robert Rodgers, PhD from Parkinsons Recovery, Lexie offers detailed information about her experience with taking LDN. She has been able to titrate off her daily use of traditional PD medications, while controlling and reversing most of her own PD symptoms, thanks to LDN. Many doctors are not familiar with LDN as a treatment for Parkinson's symptoms. It is a prescription medication, so a prescription from a doctor is necessary. Lexie offers suggestions about how to discuss a request for a LDN prescription from your doctor and offers specific suggestions about where to get LDN once a prescription is in hand. This interview was originally published in Pioneers of Recovery, a series of stories by people who succeeded in reversing their Parkinson's symptoms using one modality or another. Lexie's story of recovery centers on the use of LDN which has been so beneficial to her own recovery from Parkinsons Disease.

Low Dose Naltrexone (LDN) Therapy: An Evidence Based Review and Case Histories

Told with humor and honesty, Wouk pulls the reader through his thought processes as he watches his mind dissolve from the subcortical dementia caused by his particular variety of MS.

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

HONEST MEDICINE introduces four lifesaving treatments that have been effectively treating--and in some cases curing--people for 25-90 years. However, for reasons of profitability (or lack thereof), these treatments have not been universally accepted. The treatments are: Low Dose Naltrexone for autoimmune diseases (e.g., multiple sclerosis, lupus, rheumatoid arthritis, Crohn's disease, etc.)